Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

Approximately 52 investigative site globally are planned to participate in this study. An
estimated 300 subjects with poorly controlled T2DM and moderate renal impairment will be
randomly assigned to receive bexagliflozin tablets, 20 mg, or placebo in equal ratio for 24
weeks.

Inclusion Criteria:

1. Males or females with T2DM with inadequate glycemic control

2. Diagnosis of moderate renal impairment

4) Body Mass Index ≤ 45 kg/m2

Exclusion Criteria:

1. Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young

2. Women who are pregnant or nursing

3. Subjects who are receiving renal replacement therapy or have undergone renal
transplantation